Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
1(17%)
Results Posted
100%(4 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
1
17%
Ph phase_4
1
17%
Ph phase_3
3
50%

Phase Distribution

1

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
3(60.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 33 (60.0%)
Phase 41 (20.0%)

Trials by Status

completed467%
recruiting117%
terminated117%

Recent Activity

1 active trials
Showing 5 of 6
completedphase_3

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

NCT05696080
completedphase_3

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

NCT05393037
terminated

MISP 60528 Pneumococcal Vaccination

NCT04845945
recruitingphase_4

Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15

NCT06731374
completedphase_3

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

NCT05420961
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05696080Phase 3

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

Completed
NCT05393037Phase 3

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

Completed
NCT04845945

MISP 60528 Pneumococcal Vaccination

Terminated
NCT06731374Phase 4

Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15

Recruiting
NCT05420961Phase 3

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

Completed
NCT05489328Phase 1

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6